Phase 1 Clinical Trial of FluBHPVE6E7 Immunotherapy for HPV16-Associated Oropharyngeal Cancer
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-65
SponsorBlueSky Immunotherapies GmbH
About this trial
A clinical study of an immunotherapy in patients with head or neck cancers associated with the HPV16 virus
Eligibility criteria
Qualifiers
T2N2-3, M0
T3N0-3, M0
T4N0-3, M0
Primary tumour accessible for biopsy and intratumoural administration
Disqualifiers
Distant metastases
Secondary, not HPV16-associated, malignancy
History of malignancy other than the target malignancy to be investigated in this trial unless a complete remission was achieved at least 2 years prior to study entry AND no additional therapy is required during the study period
Clinically significant out of range haematological, renal or hepatic laboratory tests which cannot be explained by the underlying disease
Trial design
Treatments tested in this trial
- FluBHPVE6E7
Treatment groups
12 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov